Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1
A Phase I Study to Investigate the Safety, Tolerability and Pharmacodynamic Effects of SLIT(Tablets) With Recombinant Bet v1 Given in Single Rising Doses and in Higher Multi Dose Regimens to Subjects Sensitised to Birch Pollen
Sponsor: Quintiles, Inc.
Listed as NCT00396149, this PHASE1 trial focuses on Birch Pollen-Related Rhinoconjunctivitis and Rhinitis, Allergic, Seasonal and remains completed. Sponsored by Quintiles, Inc., it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Aug 2017 [monthly]
Completed PHASE1
First recorded
Nov 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Quintiles, Inc.
- Stallergenes Greer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Copenhagen, Denmark